Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 881-895

  Loo, Angela S ^a   Muhsin, Saif A ^a   Walsh, Thomas J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Antifungal; Mechanisms; Toxicokinetics

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIHISTAMINIC AGENT; APOTHECON; CORTICOSTEROID; DIPHENHYDRAMINE; ERGOSTEROL; HYDROCORTISONE; LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIFUNGAL ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CHILL; DISTRIBUTION VOLUME; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FLANK PAIN; FLUSHING; GLOMERULUS; HEADACHE; HUMAN; HYPOXIA; INFUSION RELATED REACTION; KIDNEY TUBULE; LEG PAIN; LIPID PEROXIDATION; LIVER DISEASE; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL (TOPIC); SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TOXICOKINETICS; URTICARIA; VASOCONSTRICTION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; MYCOSES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84886636893     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.827168     Document Type: Article

References (130)

1. Andreoli TE. On the anatomy of amphotericin B-cholesterol pores in lipid bilayer membranes. Kidney Int 1973;4:337-45
2. Ostrosky-Zeichner L, Marr K, Rex J, Cohen S. Amphotericin B: Time for a new "gold standard". Clin Infect Dis 2003;37(3):415-25
3. Important paper underscoring the need for a less toxic formulation of AmB. 3. Fungizone for infusion [package insert]. Squibb, New York; 1959
4. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006;27S:S12-16
5. AmBisome (amphotericin B) liposome for injection. [package insert]Gilead Sciences; San Dimas, CA: 2012
6. Rex J, Stevens D. Systemic antifungal agents. In: Mandell G, Bennett J, Dolin R, editors. Mandell, douglas, and Bennett's principles and practice of infectious diseases. 7th edition. Churchill Livingstone Elsevier; Philadelphia, PA: 2009. p. 549-63
7. Adler-Moore JP, Proffitt RT. Amphotericin b lipid preparations: What are the differences? Clin Microbiol Infect 2008;14(Suppl 4):25-36
8. Hamill RJ. Amphotericin b formulations: A comparative review of efficacy and toxicity. Drugs 2013;73:919-34
9. Herbrecht R, Natarajan-Arne S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003;4(8):1277-87
10. Andes D, Safdar N, Marchillo K, Conklin R. Pharmacokinetic- pharmacodynamic comparison of amphotericin b (AMB and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006;50(2):674-84
11. Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin b (AmBisome) and amphotericin b deoxycholate in humans. Antimicrob Agents Chemother 2002;46(3):828-33
12. Adler-Moore JP, Proffitt RT. Ambisome: Long circulating liposomal formulation of amphotericin B. In: Woodle MC, Storm G, editors. Long-circulating liposomes: Old drugs, new therapeutics. Springer-Verlag; New York, NY: 1998. p. 185-206
13. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993;3(3):429-50
14. Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002;46(3):834-40
15. Bellman R, Egger P, Wiedermann C. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis 2003;36(11):1500-1
16. Brajtburg J, Elberg S, Bolard J, et al. Interaction of plasma proteins and lipoproteins with amphotericin B.J Infect Dis 1984;149(6):986-97
17. Walsh T, Goodman J, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001;45(12):3487-96
18. Wasan K, Lopez-Berestein G. Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Ann N Y Acad Sci 1994;730:93-106
19. Wasan K, Lopez-Berestein G. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target 1994;2:373-80
20. Bekersky I, Boswell GW, Hiles R, et al. Safety, toxicokinetics, and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats. Pharm Res 2000;17:1494-502
21. Wasan K, Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis 1996;23(5):1126-38
22. Legrand P, Vertut-Doi A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996;37(3):519-33
23. Mehta R, Poddar S, Kalidas M, et al. Role of macrophages in the candidacidal activity of liposomal amphotericin B. J Infect Dis 1997;175(1):214-17
24. Walsh T, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998;42(9):2391-8
25. van Etten E, ten Kate M, Snijders S, Bakker-Woudenberg I. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system. Antimicrob Agents Chemother 1998;42(7):1677-81
26. Baginski M, Sternal K, Czub J, Borowski E. Molecular modeling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim Pol 2005;52(3):655-8
27. Romero E, Valdivieso E, Cohen B. Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes. J Membr Biol 2009;230:69-81
28. Dotis J, Simitsopoulou M, Dalakiouridou M, et al. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2006;50(3):868-73
29. De Kruijff B, Demel RA. Polyene antibiotic-sterol interactions in membranes of acholeplasma laidlawii cells and lecithin liposomes. III. Molecular structure of the polyene antibiotic-cholesterol complexes. Biochim Biophys Acta 1974;339:57-70
30. Cohen BE. Amphotericin B membrane action: Role for two types of ion channels in eliciting cell survival and lethal effects. J Membr Biol 2010;238:1-20
31. Hsu S, Burnette R. The effect of amphotericin B on the K-channel activity of MDCK cells. Biochim Biophys Acta 1993;1152:189-91
32. Hsu S, Burnette R. Characterization of the effects of amphotericin B on ion channels in MDCK cells using the patch-clamp technique. Biochim Biophys Acta 1997;1329:26-38
33. Baran M, Borowski E, Mazerski J. Molecular modeling of amphotericin B-ergosterol primary complex in water II. Biophys Chem 2009;141:162-8
34. Brutyan RA, McPhie P. On the one-sided action of amphotericin B on lipid bilayer membranes. J Gen Physiol 1996;107:69-78
35. Neumann A, Baginski M, Czub J. How do sterols determine the antifungal activity of amphotericin B? Free energy of binding between the drug and its membrane targets. J Am Chem Soc 2010;132(51):18266-72
36. Gray KC, Palacios DS, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci USA 2012;109(7):2234-9
37. Palacios D, Anderson T, Burke M. A post-PKS oxidation of amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity. J Am Chem Soc 2007;129(45):13804-5
38. Phillips A, Sudbery I, Ramsdale M. Apoptosis induced by environmental stresses and amphotericin B in candida albicans. Proc Natl Acad Sci USA 2003;100(24):14327-32
39. Mousavi S, Robson G. Oxidative and amphotericin B-mediated cell death in the opportunistic pathogen aspergillus fumigatus is associated with an apoptotic-like phenotype. Microbiology 2004;150(6):1937-45
40. Al-Dhaheri RS, Douglas LJ. Apoptosis in candida biofilms exposed to amphotericin B. J Med Mcirobiol 2009;59(2):149-57
41. Shaha C. Apoptosis in Leishmania species & its relevance to disease pathogenesis. Indian J Med Res 2006;123(3):233-44
42. Bernardi P, Rasola A. Calcium and cell death: The mitochondrial connection. Subcell Biochem 2007;45:481-506
43. Sokol-Anderson M, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of candida albicans. J Infect Dis 1986;154(1):76-83
44. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in aspergillus terreus. Antimicrob Agents Chemother 2008;52(4):1553-5
45. Lamy-Freund M, Ferreira V, Schreier S. Mechanism of inactivation of the polyene antibiotic amphotericin B. Evidence for radical formation in the process of autooxidation. J Antibiot (Tokyo ;38(6):753-7
46. Sangalli-Leite F, Scorzoni L, Mesa-Arango A, et al. Amphotericin B mediates killing in cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect 2011;13:457-67
47. Proffitt R, Satorius A, Chiang S, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28(Suppl B):49-61
48. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: A review. J Chemother 2000;12(6):463-70
49. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32(5):686-93
50. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71
51. Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis. Medicine 2010;89(4):236-44
52. Noguchi S, Takahashi N, Ito M, et al. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. Int J Clin Oncol 2012; [Epub ahead of print] Available from: Http://www.ncbi.nlm.nih.gov/ pubmed/23076821
53. Shigemi A, Matsumoto K, Ikawa K, et al. Safety analysis of liposomal amphotericin B in adult patients: Anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. Int J Antimicrob Agents 2011;38:417-20
54. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31(5):1155-63
55. Wasan K, Brocks D, Lee S, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: Implications for drug discovery. Nat Rev Drug Discov 2008;7(1):84-99
56. Wasan K, Morton R, Rosenblum M, Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein. J Pharm Sci 1994;83(7):1006-10
57. Wasan K, Rosenblum M, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994;38(2):223-7
58. Groll AH, Muller FC, Piscitelli SC, Walsh TJ. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998;210(4):265-73
59. Lee J, Amantea M, Francis P, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38(4):713-18
60. Andreoli TE, Monahan M. The interaction of polyene antibiotics with thin lipid membranes. J Gen Physiol 1968;52(2):300-25
61. Mehta R, Lopez-Berestein G, Hopfer R, et al. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta BBABiomembr 1984;770(2):230-4
62. Sperry P, Cua D, Wetzel S, Adler-Moore J. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med Mycol 1998;36(3):135-41
63. Adler-Moore J, Proffitt R. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002;49(Suppl 1):21-30
64. Butler WT, Hill GJ II, Szwed CF, Knight V. Amphotericin B renal toxicity in the dog. J Pharmacol Exp Ther 1963;143:47-56
65. Bullock WE, Luke RG, Nuttall CE, Bhathena D. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 1976;10(3):555-63
66. Bhathena DB, Bulllock WE, Nuttall CE, Luke RG. The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. A study of biopsies by light, electron and immunofluorescence microscopy. Clin Nephrol 1978;9(3):103-10
67. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf 1990;5(2):94-108
68. Gerkens JF, Branch RA. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980;214(2):306-11
69. Gerkens JF, Heidemann HT, Jackson EK, Branch RA. Effect of aminophylline on amphotericin B nephrotoxicity in the dog. J Pharmacol Exp Ther 1983;244(3):609-13
70. Heidemann HT, Gerkens JF, Jackson EK, Branch RA. Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat. Naunyn Schmiedebergs Arch Pharmacol 1983;324(2):148-52
71. Sabra R, Takahashi K, Branch RA, Badr KF. Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: A micropuncture study. J Pharmacol Exp Ther 1990;253(1):34-7
72. . Study of mechanisms of AmB-induced nephrotoxicity with focus on tubuloglomerular feedback. 72. Shahid M, Francis J, Majid DSA. Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Ren Physiol 2008;295(6):F1836-44
73. Falk R, Hacham M, Nyska A, et al. Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. J Antimicrob Chemother 2005;55(5):713-20
74. Louie A, Baltch AL, Franke MA, et al. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: An effect that is attenuated by pentoxifyline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother 1994;34(6):975-87
75. Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991;87(6):2097-107
76. Blum SF, Shohet SB, Nathan DG, Gardner FH. The effect of amphotericin B on erythrocyte membrane cation permeability: Its relation to in vivo erythrocyte survival. J Lab Clin Med 1969;73(6):980-7
77. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995;70(2):235-41
78. Yano T, Itoh Y, Kawamura E, et al. Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration. Antimicrob Agents Chemother 2009;53(4):1420-6
79. Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004;38:1031-8
80. Walev I, Bhakdi S. Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob Agents Chemother 1996;40(5):1116-20
81. Gouge TH, Andriole VT. An experimental model of amphotericin B nephrotoxicity with renal tubular acidosis. J Lab Clin Med 1971;78(5):713-24
82. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: Standard of care? West J Med 1995;162(4):313-17
83. Tolins JP, Raji L. Chronic amphotericin B nephrotoxicity in the rat, protective effect of prophylactic salt loading. Am J Kidney Dis 1988;11(4):313-17
84. Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989;298(5):299-304
85. Llanos A, Cieza J, Bernardo JF, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40(2):302-8
86. Branch RA. Prevention of amphotericin b-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 1988;148(11):2389-94
87. Cleary JD, Schwartz M, Rogers PD, et al. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 2003;23(8):966-73
88. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Dis Clin Infect Dis 1995;20:755-61
89. Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: Analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003;36(10):1213-20
90. Sau K, Mambula SS, Latz E, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003;278(39):37561-8
91. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995;38:459-65
92. Baronti R, Masini E, Bacciottini L, Mannaioni P. Differential effects of amphotericin B and liposomal amphotericin B on inflammatory cells in vitro. Inflamm Res 2002;51:259-64
93. Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (Madr ;33(7):779-86
94. Olson F, Mayhew E, Maslow D, et al. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982;18(2):167-76
95. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-c5a antibody. Circulation 1999;99(17):2302-9
96. Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114(8):664-6
97. Burks LC, Aisner J, Fortner CL, Wiernik PH. Meperidine for the treatment of shaking chills and fever. Arch Intern Med 1980;1401:483-4
98. Cleary JD, Chapman SW, Nolan RL. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother 1992;36(5):977-81
99. Tynes BS, Utz JP, Bennett JE, Alling DW. Reducing amphotericin B reactions: A double blind study. Am Rev Respir Dis 1963;87:264-8
100. Yeo E, Ryu J, Cho Y, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1 Blood 2006;107:916-23
101. Hoeprich PD. Clinical use of amphotericin B and derivatives: Lore, mystique, and fact. Clin Infect Dis 1992;14(Suppl 1):S114-19
102. Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: A randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2009;51(2):225-32
103. Brandiss MW, Wolff SM, Moores R, Stohlman F. Anemia induced by amphotericin B. JAMA 1964;189(9):663-6
104. Lin A, Goldwasser E, Bernard E, Chapman S. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1989;161:348-51
105. MacGregor R, Bennett J, Erslev A. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob Agents Chemother 1978;14(2):270-3
106. Mahmud H, Mauro D, Quadri S, et al. Triggering of suicidal erythrocyte death by amphotericin B. Cell Physiol Biochem 2009;24:263-70
107. Slisz M, Cybulska B, Mazerski J, et al. Studies of the effects of antifungal cationic derivatives of amphotericin B on human erythrocytes. J Antibiot (Tokyo ;57(10):669-78
108. Burke D, Lal R, Finkel KW, et al. Acute amphotericin B overdose. Ann Pharmacother 2006;40:2254-9
109. Wang GS, Banerji S, Roussil TK, Heard KJ. Survival after amphotericin B overdose treated with plasmapheresis. Ann Pharmacother 2013;47(2):e9
110. Larabi M, Yardley V, Loiseau PM, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 2003;47(12):3774-9
111. Jensen G, Skenes C, Bunch T, et al. Determination of the relative toxicity of amphotericin B formulations: A red blood cell potassium release assay. Drug Deliv 1999;6(2):81-8
112. Charvalos E, Tzatzarakis MN, Van Bambeke F, et al. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J Antimicrob Chemother 2005;57(2):236-44
113. Chan C, Tuazon C, Lessin L. Amphotericin-B-induced thrombocytopenia. Ann Intern Med 1982;96(3):332-3
114. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in india. N Engl J Med 2010;362:504-12
115. Sloand E, Kumar P, Yu M, Klein H. Effect of amphotericin B and fluconazole on platelet membrane glycoproteins. Transfusion 1994;34(5):415-20
116. Kulpa J, Zaroulis C, Good R, Kutti J. Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion. Transfusion 1981;21(1):74-6
117. Hussein M, Fletcher R, Long T, et al. Transfusion platelets 2h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med 1998;8:43-7
118. Miller M. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984;131:1245-7
119. Wingard JR, Leather H. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis 2005;41:301-7
120. Olin JL, Spooner LM. Amphotericin B-associated hyperbilirubinemia: Case report and review of the literature. Pharmacotherapy 2006;26(7):1011-17
121. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005;41(3):301-7
122. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40(5-6):511-20
123. Chamilos G, Luna M, Lewis R, et al. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. Clin Ther 2007;29(9):1980-6
124. Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012;54(Suppl 1):S55-60
125. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56(12):1724-32
126. Gamaletsou MN, Daikos G, Walsh TJ, et al. Phenotypic and molecular resistance patterns of Candida species in patients with candidemia and hematologic malignancies [abstract O465]. Programme of the 23rd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID); 2013
127. Denning DW, Perlin DS. Azole resistance in Aspergillus: A growing public health menace. Future Microbiol 2011;6(11):1229-32
128. Wilcock BC, Endo MM, Uno BE, Burke MD. C2¢-OH of amphotericin B plays an important role in binding the primary sterol of human cells but not yeast cells. J Am Chem Soc 2013;135(23):8488-91
129. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11(12):1463-71
130. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: Evaluation of United Kingdom compassionate use data. Arch Intern med 1995;155:1093-8